Literature DB >> 25765151

Feasibility and Safety of MR-Guided Focused Ultrasound Lesioning in the Setting of Deep Brain Stimulation.

Robert Dallapiazza1, Mohamad Khaled, Matthew Eames, John Snell, M Beatriz Lopes, Max Wintermark, W Jeffrey Elias.   

Abstract

BACKGROUND: Patients treated with deep brain stimulation (DBS) often develop symptom progression. If safe, focused ultrasound (FUS) lesioning could be used for patients unable to undergo further DBS surgery.
OBJECTIVE: To test the feasibility and safety of MR-guided FUS surgery in the setting of a previously implanted DBS system.
METHODS: Three preclinical experiments were designed to test feasibility and safety. Hydrogels were implanted with an electrode, and FUS lesions were targeted adjacently. Cadavers were implanted with a thalamic electrode, and FUS lesions were targeted in the contralateral thalamus. Finally, DBS systems were implanted in swine, and FUS lesioning was targeted to the contralateral thalamus, MRI was used to assess the treatments, and histological analyses were performed at 2 days and at 1 month.
RESULTS: In gel experiments and cadavers, FUS resulted in target heating to 29-32°C without any heating at the electrode. In animal experiments, there were no FUS-related MRI signal changes near the electrode. Histological analysis showed typical FUS lesions with no evidence of damage surrounding the electrode tracts.
CONCLUSIONS: FUS is feasible in the setting of a preimplanted DBS device. There was minimal heating of the device during the procedure and no apparent FUS-related tissue injury.
© 2015 S. Karger AG, Basel.

Entities:  

Year:  2015        PMID: 25765151     DOI: 10.1159/000368908

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  1 in total

Review 1.  Proceedings of the Third Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies.

Authors:  P Justin Rossi; Aysegul Gunduz; Jack Judy; Linda Wilson; Andre Machado; James J Giordano; W Jeff Elias; Marvin A Rossi; Christopher L Butson; Michael D Fox; Cameron C McIntyre; Nader Pouratian; Nicole C Swann; Coralie de Hemptinne; Robert E Gross; Howard J Chizeck; Michele Tagliati; Andres M Lozano; Wayne Goodman; Jean-Philippe Langevin; Ron L Alterman; Umer Akbar; Greg A Gerhardt; Warren M Grill; Mark Hallett; Todd Herrington; Jeffrey Herron; Craig van Horne; Brian H Kopell; Anthony E Lang; Codrin Lungu; Daniel Martinez-Ramirez; Alon Y Mogilner; Rene Molina; Enrico Opri; Kevin J Otto; Karim G Oweiss; Yagna Pathak; Aparna Shukla; Jonathan Shute; Sameer A Sheth; Ludy C Shih; G Karl Steinke; Alexander I Tröster; Nora Vanegas; Kareem A Zaghloul; Leopoldo Cendejas-Zaragoza; Leonard Verhagen; Kelly D Foote; Michael S Okun
Journal:  Front Neurosci       Date:  2016-04-06       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.